Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Bullet list of each inclusion criterium:~1. Must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.~2. At least 18 years of age at the time of signing the informed consent form.~3. Diagnosed with generalized Myasthenia Gravis (gMG) with confirmed documentation and supported by at least 1 of the following:~   1. History of abnormal neuromuscular transmission demonstrated by single fiber electromyography or repetitive nerve stimulation~  2. History of positive edrophonium chloride test~  3. Demonstrated improvement in Myasthenia Gravis (MG) signs upon treatment with oral acetylcholinesterase (AChE) inhibitors as assessed by the treating physician~4. Meeting the clinical criteria as defined by the Myasthenia Gravis Foundation of America (MGFA) class II, III, IVa, or IVb~Exclusion Criteria:~Bullet list of each exclusion criterium:~1. Are pregnant or lactating, or intend to become pregnant during the study or within 90 days after the last dose of Investigational Medicinal Product.~2. Has any of the following medical conditions:~   1. Clinically significant uncontrolled active or chronic bacterial, viral, or fungal infection at screening~  2. Any other known autoimmune disease that, in the opinion of the investigator, would interfere with an accurate assessment of clinical symptoms of myasthenia gravis or put the participant at undue risk.~  3. History of malignancy unless deemed cured by adequate treatment with no evidence of reoccurrence for ≥3 years before the first administration of the IMP. Participants with the following cancers can be included at any time:~      * adequately treated basal cell or squamous cell skin cancer~     * carcinoma in situ of the cervix~     * carcinoma in situ of the breast~     * incidental histological findings of prostate cancer (TNM Classification of Malignant Tumors stage T1a or T1b).~  4. Clinical evidence of other significant serious diseases, or the participant has had a recent major surgery, or who have any other condition that, in the opinion of the investigator, could confound the results of the study or put the participant at undue risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- efgartigimod PH20 SC (Type: EXPERIMENTAL): Patients receiving efgartigimod PH20 subcutaneous (SC) treatment
- efgartigimod (Type: EXPERIMENTAL): Patients receiving efgartigimod intravenous (IV) treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete